



May 3, 2017

## **Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists**

PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) being held May 6 - 9, 2017 in San Diego, CA.

The SECURE study evaluated the clinical benefit of the investigational transdermal contraceptive patch AG200-15, known as Twirla<sup>®</sup>, in a diverse, real-world population of women reflective of current weight trends in the United States. The ePoster will include efficacy and safety findings for the overall population and pre-specified body mass index (BMI) categories, in addition to results on the bleeding profile that have not previously reported.

The presentation details are as follows:

**Poster Title:** Results from the SECURE Trial, a Phase 3 Study of the AG200-15 Investigational Transdermal Contraceptive Patch  
**Poster ID:** 22A  
**Poster Session:** ePoster Session A  
**Room:** Ballroom 20A  
**Date and Time:** Saturday, May 6, 2017  
**Time:** 11:00 am — 12:00 pm PT  
**Presenter:** Anita Nelson, MD, Professor and Chair, Obstetrics and Gynecology, College of Osteopathic Medicine of the Pacific

For more information, please visit the company website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com).

### **About Agile Therapeutics, Inc.**

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla<sup>®</sup>, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion<sup>®</sup>, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com). The company may occasionally disseminate material, nonpublic information on the company website.

Source: Agile Therapeutics

Investor Relations Contact:  
Mary Coleman  
Agile Therapeutics  
609-356-1921  
[mcoleman@agiletherapeutics.com](mailto:mcoleman@agiletherapeutics.com)

Media Relations Contact:  
Glenn Silver  
Lazar Partners Ltd.  
646-871-8485  
[gsilver@lazarpartners.com](mailto:gsilver@lazarpartners.com)